Royalty Report: Drugs, Multiple Sclerosis, Pharmaceuticals – Collection: 301608

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Multiple Sclerosis
  • Pharmaceuticals
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 301608

License Grant
Danish Licensee acquires the patent family from Swiss Licensor, a related party. Under the Transfer Agreement, the Company obtained, among other things, Licensors patents and associated know-how related to DMF formulations and delivery systems (the Licensor IP).
License Property
Dimethyl fumarate (DMF), an immunomodulator, as a therapeutic to improve the health of patients with immune disorders, including MS.  Dimethyl fumarate (DMF) is the methyl ester of fumaric acid.

Licensor develops and files patents for, among other things, formulations and dosing regimens of DMF.

Field of Use
Dimethyl fumarate is used to treat adults with various forms of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control)

IPSCIO Record ID: 3535

License Grant
As of the Effective Date and subject to the terms and conditions of this Agreement Seller shall sell, transfer and assign to the Buyer the Seller's Patent Rights, free of any Third Party Rights.
License Property
The Seller has developed intellectual property pertaining to various formulations and new chemical entities of fumaric acid esters and developed certain know-how related hereto.
Field of Use
Fumaric acid is used in oral pharmaceutical formulations and food products, and is generally regarded as a relatively nontoxic and nonirritant material.

Fumaric acid preparations are used as long term and effective treatment of psoriasis.

IPSCIO Record ID: 292649

License Grant
The Company received an exclusive, worldwide license to develop and commercialize VUMERITY.
License Property
VUMERITY, a novel fumarate for the treatment of RMS (relapsing multiple sclerosis).
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 146513

License Grant
Licensors of Denmark grant the Swiss Licensee for the U.S. License (U.S. Licensee) and its Affiliates, a perpetual, irrevocable, co-exclusive license, to make any and all use in the United States of the licensed intellectual property owned, registered or otherwise protected or enjoyable under the laws of the United States by Licensor, such additional party or such controlled affiliate, as the case may be, with the right to sublicense, transfer or assign.  

The Licensor of Denmark grants to the Swiss Licensee of the U.S. License (U.S. Licensee), and its Affiliates, a perpetual, irrevocable, exclusive, even as to Licensor, each of the additional parties and their respective affiliates,  license to the U.S. Licensed Intellectual Property, with the right to sublicense, transfer or assign, and to make any and all use thereof in the United States.

An exclusive worldwide, other than U.S., Licensor hereby grants to designated countries licensee and its Affiliates, effective at all times during the designated countries license term, a perpetual, irrevocable, exclusive, even as to Licensor, each of the Additional Parties and their respective Affiliates, license to all Licensed Intellectual Property owned, registered or otherwise protected or enjoyable under the Laws of any country in the world other than the United States with the right to sublicense, transfer or assign, and to make any and all use thereof in the Designated Countries.

License Property
The licensed property is related to the treatment of any human disease or condition using dimethyl fumarate; related to Licensor’s FP-187 product, including any and all Patents, Confidential Intellectual Property Information, regulatory exclusivity or regulatory clearance related thereto and all other Intellectual Property rights related to Licensor’s FP-187 product, relating to the manufacture, formulation, method or means of delivery or administration of any therapeutic product for the treatment of any human disease or condition using dimethyl fumarate.

Tecfidera means the product sold as of the Agreement Date by Licensee under Licensee’s tradename and marketing authorization for its oral formulation of dimethyl fumarate indicated for the treatment of multiple sclerosis at the recommended dose of 480 mg/day associated with NDA No. 204063 and equivalent approvals in Designated Countries.

Field of Use
The product use is for multiple sclerosis.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.